The TEASE-1 trial reveals gildeuretinol's potential to reduce vision loss in Stargardt disease, offering hope for future treatments.
Benjamin Bakall, MD, PhD
Advertisement
Articles by Benjamin Bakall, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Idebenone accepted by FDA for priority review for Leber Hereditary Optic Neuropathy
2
Luxa Biotechnology announces clinical trial results for treatment of AMD
3
STAAR Surgical confirms expiration of “window shop” period in Alcon merger agreement
4
The European Commission grants marketing authorization for EYLUXVI
5
.png "Optometry Times"){kind=logo}
